SCI Pharmtech (4119.TW) Stock Price

SCI Pharmtech Price

TWSE·CLOSED
48.10TWD+0.05 (+0.10 %)
Market closed

Over the last 19 years SCI Pharmtech grew revenue by 5.2% annually, reaching 1.34 B TWD. Earnings per share have declined at 6.6% per year over the last 15 years. For SCI Pharmtech, the net margin of 8.0% is up versus 6.4% a few years ago. At today's price the dividend yield works out to roughly 3.12%. The payout ratio is around 168% of earnings. The dividend has grown at 1.9% per year over the past 19 years. The consensus 12-month price target for SCI Pharmtech is 77.97 TWD, about 62.1% above where the stock trades today. Of 9 analysts, 6 rate the stock a buy — an overall Buy consensus. The stock trades about 19% above its 52-week low.

SCI Pharmtech stock price

Volume
Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of SCI Pharmtech over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how SCI Pharmtech stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing SCI Pharmtech's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

SCI Pharmtech Stock Price History
DateSCI Pharmtech Price
8/3/202648.10 TWD
7/31/202648.05 TWD
7/30/202648.00 TWD
7/29/202648.55 TWD
7/28/202650.10 TWD
7/27/202651.70 TWD
7/24/202651.90 TWD
7/23/202649.15 TWD
7/22/202649.80 TWD
7/21/202648.40 TWD
7/20/202646.60 TWD
7/17/202646.35 TWD
7/16/202647.00 TWD
7/15/202646.00 TWD
7/14/202644.60 TWD
7/13/202645.30 TWD
7/10/202645.50 TWD
7/9/202645.50 TWD
7/8/202644.75 TWD
7/7/202644.75 TWD
7/6/202645.35 TWD
7/3/202645.10 TWD
7/2/202645.10 TWD
7/1/202644.00 TWD
6/30/202644.80 TWD
6/29/202644.50 TWD
6/26/202644.50 TWD
6/25/202644.65 TWD
6/24/202644.25 TWD
6/23/202643.20 TWD
6/22/202643.40 TWD
6/18/202644.20 TWD
6/17/202643.35 TWD
6/16/202642.10 TWD
6/15/202642.15 TWD
6/12/202641.60 TWD
6/11/202642.30 TWD
6/10/202642.95 TWD
6/9/202642.75 TWD
6/8/202641.10 TWD
6/5/202641.30 TWD
6/4/202640.90 TWD
6/3/202641.05 TWD
6/2/202641.00 TWD
6/1/202641.90 TWD
5/29/202640.80 TWD
5/28/202640.70 TWD
5/27/202641.00 TWD
5/26/202641.30 TWD
5/25/202641.30 TWD
5/22/202642.25 TWD
5/21/202643.05 TWD
5/20/202642.50 TWD
5/19/202642.40 TWD
5/18/202641.60 TWD
5/15/202640.40 TWD
5/14/202640.95 TWD
5/13/202641.60 TWD
5/12/202642.10 TWD
5/11/202644.30 TWD
5/8/202646.65 TWD
5/7/202647.30 TWD
5/6/202647.10 TWD
5/5/202647.10 TWD
5/4/202647.15 TWD
4/30/202647.80 TWD
4/29/202648.20 TWD
4/28/202647.50 TWD
4/27/202647.75 TWD
4/24/202648.25 TWD
4/23/202647.10 TWD
4/22/202648.00 TWD
4/21/202648.05 TWD
4/20/202648.40 TWD
4/17/202648.55 TWD
4/16/202650.00 TWD
4/15/202650.00 TWD
4/14/202650.40 TWD
4/13/202650.80 TWD
4/10/202650.50 TWD
4/9/202651.00 TWD
4/8/202652.30 TWD
4/7/202652.10 TWD
4/2/202651.60 TWD
4/1/202651.90 TWD
3/31/202650.90 TWD
3/30/202651.20 TWD
3/27/202652.50 TWD
3/26/202652.70 TWD
3/25/202652.30 TWD
3/24/202652.20 TWD
3/23/202651.80 TWD
3/20/202652.30 TWD
3/19/202652.80 TWD
3/18/202654.20 TWD
3/17/202654.80 TWD
3/16/202654.80 TWD
3/13/202654.10 TWD
3/12/202653.40 TWD
3/11/202655.00 TWD
3/10/202653.60 TWD
3/9/202652.00 TWD
3/6/202652.20 TWD
3/5/202651.00 TWD
2/26/202653.60 TWD
2/25/202653.10 TWD
2/24/202653.70 TWD
2/23/202652.80 TWD
2/11/202652.00 TWD
2/10/202653.10 TWD
2/9/202652.10 TWD
2/6/202651.90 TWD
2/5/202652.30 TWD
2/4/202652.20 TWD
2/3/202651.10 TWD
2/2/202651.70 TWD
1/30/202651.90 TWD
1/29/202653.50 TWD
1/28/202653.70 TWD
1/27/202653.70 TWD
1/26/202653.90 TWD
1/23/202653.90 TWD
1/22/202653.50 TWD
1/21/202652.40 TWD
1/20/202653.10 TWD
1/19/202653.90 TWD
1/16/202653.50 TWD
1/15/202652.70 TWD
1/14/202652.30 TWD
1/13/202651.60 TWD
1/12/202651.20 TWD
1/9/202651.20 TWD
1/8/202649.15 TWD
1/7/202648.80 TWD
1/6/202647.60 TWD
1/5/202647.85 TWD
1/2/202648.55 TWD
12/31/202548.70 TWD
12/30/202548.90 TWD
12/29/202549.05 TWD
12/26/202548.95 TWD
12/24/202548.90 TWD
12/23/202548.90 TWD
12/22/202549.10 TWD
12/19/202549.35 TWD
12/18/202548.25 TWD
12/17/202548.10 TWD
12/16/202548.20 TWD
12/15/202549.55 TWD
12/12/202548.55 TWD
12/11/202548.10 TWD
12/10/202547.25 TWD
12/9/202547.50 TWD
12/8/202547.70 TWD
12/5/202548.25 TWD
12/4/202548.85 TWD
12/3/202548.35 TWD
12/2/202549.35 TWD
12/1/202548.75 TWD
11/28/202549.20 TWD
11/27/202549.75 TWD
11/26/202549.80 TWD
11/25/202548.70 TWD
11/24/202547.45 TWD
11/21/202547.00 TWD
11/20/202548.55 TWD
11/19/202548.55 TWD
11/18/202548.40 TWD
11/17/202549.15 TWD
11/14/202549.75 TWD
11/13/202549.95 TWD
11/12/202550.90 TWD
11/11/202550.70 TWD
11/10/202552.70 TWD
11/7/202556.20 TWD
11/6/202557.00 TWD
11/5/202556.20 TWD
11/4/202556.20 TWD
11/3/202556.60 TWD
10/31/202557.60 TWD
10/30/202557.70 TWD
10/29/202558.40 TWD
10/28/202559.30 TWD
10/27/202559.90 TWD
10/23/202559.30 TWD
10/22/202559.40 TWD
10/21/202558.30 TWD
10/20/202558.10 TWD
10/17/202559.10 TWD
10/16/202558.20 TWD
10/15/202558.00 TWD
10/14/202558.30 TWD
10/13/202558.90 TWD
10/9/202559.70 TWD
10/8/202559.10 TWD
10/7/202559.10 TWD
10/3/202558.90 TWD
10/2/202559.70 TWD
10/1/202560.00 TWD
9/30/202560.00 TWD
9/26/202560.20 TWD
9/25/202560.00 TWD
9/24/202559.90 TWD
9/23/202559.10 TWD
9/22/202557.70 TWD
9/19/202557.60 TWD
9/18/202557.70 TWD
9/17/202557.50 TWD
9/16/202557.60 TWD
9/15/202557.90 TWD
9/12/202558.20 TWD
9/11/202558.00 TWD
9/10/202559.70 TWD
9/9/202559.20 TWD
9/8/202561.00 TWD
9/5/202560.50 TWD
9/4/202561.20 TWD
9/3/202561.20 TWD
9/2/202561.60 TWD
9/1/202559.10 TWD
8/29/202559.40 TWD
8/28/202559.90 TWD
8/27/202559.80 TWD
8/26/202558.70 TWD
8/25/202559.50 TWD
8/22/202560.10 TWD
8/21/202559.40 TWD
8/20/202558.30 TWD
8/19/202559.30 TWD
8/18/202559.80 TWD
8/15/202560.10 TWD
8/14/202560.00 TWD
8/13/202560.30 TWD
8/12/202557.50 TWD
8/11/202557.00 TWD
8/8/202558.10 TWD
8/7/202559.20 TWD
8/6/202559.60 TWD
Access this data via the Eulerpool API
Get Free API Key

SCI Pharmtech Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2019
2.36 B TWD
705.20 M TWD
571.10 M TWD
Jan 1, 2020
2.69 B TWD
469.71 M TWD
360.12 M TWD
Jan 1, 2021
864.22 M TWD
63.31 M TWD
55.70 M TWD
Jan 1, 2022
899.74 M TWD
404.30 M TWD
308.78 M TWD
Jan 1, 2023
1.20 B TWD
163.14 M TWD
294.72 M TWD
Jan 1, 2024
1.52 B TWD
198.29 M TWD
534.68 M TWD
Jan 1, 2025
1.34 B TWD
155.25 M TWD
107.37 M TWD
Jan 1, 2026 (e)
1.41 B TWD
396.11 M TWD
116.40 M TWD

SCI Pharmtech Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 5, 2026, 8:22 AM
 
REVENUEB TWD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEB TWD
EBITM TWD
EBIT MARGIN%
NET INCOMEM TWD
NET INCOME GROWTH%
DIV.TWD
DIV. GROWTH%
SHARESM
2011201220132014201520162017201820192020202120222023202420252026e
1.041.261.291.491.811.901.301.942.362.690.860.901.201.521.341.41
4.3321.702.3815.4021.405.14-31.6349.0421.4514.18-67.874.0533.9326.50-11.824.99
29.6031.4630.6532.1336.1941.5130.3638.5839.7047.3824.0732.3729.0726.9223.7523.75
0.310.400.400.480.660.790.400.750.941.270.210.290.350.410.320.33
186.00251.00205.00295.00439.00516.00234.00516.00705.00469.0063.00404.00163.00198.00155.00396.00
17.9419.8915.8719.7924.2527.1217.9926.6129.9417.447.2944.9413.5413.0011.5428.09
90.00194.00159.00264.00373.00416.00190.00447.00571.00360.0055.00308.00294.00534.00107.00116.00
-47.37115.56-18.0466.0441.2911.53-54.33135.2627.74-36.95-84.72460.00-4.5581.63-79.968.41
2.411.582.481.713.113.844.202.154.205.800.42–0.221.251.501.50
2.12-34.4456.96-31.0581.8723.479.38-48.8195.3538.10-92.76––468.1820.00–
69.0867.1568.3382.7485.2695.2295.6595.1695.4295.2596.52109.51119.51119.51119.93119.93
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales SCI Pharmtech generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue SCI Pharmtech retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare SCI Pharmtech's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares SCI Pharmtech has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against SCI Pharmtech's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

SCI Pharmtech stock margins

The SCI Pharmtech margin analysis displays the gross margin, EBIT margin, as well as the profit margin of SCI Pharmtech. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for SCI Pharmtech.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2019
39.72 %
29.94 %
24.24 %
Jan 1, 2020
47.39 %
17.47 %
13.39 %
Jan 1, 2021
24.08 %
7.33 %
6.44 %
Jan 1, 2022
32.36 %
44.94 %
34.32 %
Jan 1, 2023
29.09 %
13.55 %
24.48 %
Jan 1, 2024
26.95 %
13.01 %
35.09 %
Jan 1, 2025
23.78 %
11.55 %
7.99 %
Jan 1, 2026 (e)
23.78 %
28.09 %
8.26 %

SCI Pharmtech Stock Revenue, EBIT, Earnings per Share

The SCI Pharmtech earnings per share therefore indicates how much revenue SCI Pharmtech has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2019
24.69 TWD
7.39 TWD
5.99 TWD
Jan 1, 2020
28.23 TWD
4.93 TWD
3.78 TWD
Jan 1, 2021
8.95 TWD
0.66 TWD
0.58 TWD
Jan 1, 2022
8.22 TWD
3.69 TWD
2.82 TWD
Jan 1, 2023
10.08 TWD
1.37 TWD
2.47 TWD
Jan 1, 2024
12.75 TWD
1.66 TWD
4.47 TWD
Jan 1, 2025
11.20 TWD
1.29 TWD
0.90 TWD
Jan 1, 2026 (e)
11.75 TWD
3.30 TWD
0.97 TWD

SCI Pharmtech business model & stock analysis

SCI Pharmtech Inc is a leading company in the pharmaceutical industry based in Zhejiang, China. The company was founded in 2003 and has since grown continuously. Today, the company employs over 100 employees and has become a key player in the global supply chain of pharmaceutical raw materials and intermediates. SCI Pharmtech Inc's business model is based on the development and production of high-quality pharmaceutical intermediates and active pharmaceutical ingredients, as well as the manufacturing of custom chemicals. The company specializes in the production and distribution process, offering its customers a comprehensive range of products that meet the highest quality and safety standards. SCI Pharmtech Inc is divided into various divisions, each specializing in specific product categories. The main divisions are API (Active Pharmaceutical Ingredients), intermediates, and custom synthesis. The API division produces active pharmaceutical ingredients for the pharmaceutical industry, which serve as the basis for drug manufacturing. The intermediates division offers pharmaceutical intermediates used in the synthesis of active pharmaceutical ingredients. The custom synthesis division provides tailored synthesis processes for customers in need of specific chemicals or intermediates. SCI Pharmtech Inc's product portfolio includes Acetamidomalonate, Carbamazepine, and Codergocrine Mesylate, among others. The company also offers custom synthesis services, involving complex chemical syntheses and innovative technologies. SCI Pharmtech Inc places great emphasis on quality and safety. The company operates according to international standards, including GMP (Good Manufacturing Practice), ISO (International Standards Organization), and CE (Conformité Européenne). SCI Pharmtech Inc's products undergo stringent quality controls to ensure compliance with the strict regulations of global pharmaceutical regulatory authorities. Another important concern of SCI Pharmtech Inc is sustainability. The company has developed a sustainable business strategy aimed at minimizing its environmental impact and conserving resources. This includes implementing efficient production processes, reducing energy consumption and CO2 emissions, as well as promoting environmental awareness among employees and customers. Overall, SCI Pharmtech Inc is a dynamic and innovative company specializing in the production of pharmaceutical intermediates and active pharmaceutical ingredients. The company takes pride in offering high-quality products that meet the highest quality and safety standards. Through its sustainable business strategy and adherence to international standards, SCI Pharmtech Inc has achieved an excellent reputation in the pharmaceutical industry and strengthened its presence in the global market.

SCI Pharmtech SWOT Analysis

Strengths

SCI Pharmtech Inc has a strong research and development team that continually innovates and develops new pharmaceutical products. This allows the company to stay competitive and offer unique solutions to market demands.

The company has established a strong reputation in the industry for its high-quality products and reliable customer service. This has led to a loyal customer base and repeat business.

SCI Pharmtech Inc has a well-established distribution network, enabling efficient and timely delivery of its products to customers worldwide. This gives the company a competitive advantage in terms of market reach and customer satisfaction.

Weaknesses

The company relies heavily on a few key suppliers for its raw materials, which poses a risk to its supply chain. Any disruptions in the supply of these materials could affect production and result in delays or shortages.

SCI Pharmtech Inc has limited diversification in terms of product offerings. This makes the company vulnerable to market fluctuations and changes in customer preferences. Diversifying its product portfolio could help mitigate this weakness.

Opportunities

The growing global healthcare industry presents significant opportunities for SCI Pharmtech Inc to expand its market presence. There is a rising demand for innovative pharmaceutical products and services, and the company can capitalize on this trend.

Expanding into new geographic markets, particularly emerging economies, can provide SCI Pharmtech Inc with access to a larger customer base and new revenue streams. This diversification can also help mitigate risks associated with being too dependent on a single market.

Threats

Increasing competition in the pharmaceutical industry poses a threat to SCI Pharmtech Inc's market share and profitability. The company must stay proactive in adapting to market dynamics and continuously improving its products and services to maintain its competitive position.

Changes in government regulations and policies can significantly impact the pharmaceutical industry. SCI Pharmtech Inc needs to closely monitor and comply with these regulations to avoid any legal or compliance issues that could hinder its operations.

Global economic uncertainties and fluctuations, such as currency exchange rates and trade disputes, may affect SCI Pharmtech Inc's financial performance. It is essential for the company to implement effective risk management strategies to mitigate these external threats.

SCI Pharmtech Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

SCI Pharmtech historical P/E ratio, EBIT multiple, and P/S ratio

SCI Pharmtech annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

SCI Pharmtech shares outstanding

The number of shares of SCI Pharmtech was 119.93 M in 2025. This indicates how many shares SCI Pharmtech is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2019
95.42 M Stocks
Jan 1, 2020
95.25 M Stocks
Jan 1, 2021
96.52 M Stocks
Jan 1, 2022
109.51 M Stocks
Jan 1, 2023
119.51 M Stocks
Jan 1, 2024
119.51 M Stocks
Jan 1, 2025
119.93 M Stocks
Jan 1, 2026 (e)
119.93 M Stocks

SCI Pharmtech stock splits

In SCI Pharmtech's history, there have been no stock splits.

SCI Pharmtech Dividend History

21 years of dividend payments · 2 consecutive increases

YearAnnual DividendYoY ChangePayments
20251.50TWD↑ 20.0%1×
Jul 1, 20251.50TWD↑ 20.0%1/1
20241.25TWD↑ 462.5%1×
20230.22TWD↓ 46.7%1×
20210.42TWD↓ 92.8%1×
20205.80TWD↑ 38.1%1×
20194.20TWD↑ 95.3%1×
20182.15TWD↓ 48.8%1×
20174.20TWD↑ 9.4%1×
20163.84TWD↑ 23.4%1×
20153.11TWD↑ 81.5%1×

SCI Pharmtech dividend history and estimates

In 2025, SCI Pharmtech paid a dividend amounting to 1.50 TWD. Dividend means that SCI Pharmtech distributes a portion of its profits to its owners.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details
Date
Dividend
Dividend (Estimate)
Jan 1, 2018
2.15 TWD
0.00 TWD
Jan 1, 2019
4.20 TWD
0.00 TWD
Jan 1, 2020
5.80 TWD
0.00 TWD
Jan 1, 2021
0.42 TWD
0.00 TWD
Jan 1, 2023
0.22 TWD
0.00 TWD
Jan 1, 2024
1.25 TWD
0.00 TWD
Jan 1, 2025
1.50 TWD
0.00 TWD
Jan 1, 2026 (e)
0.00 TWD
1.50 TWD

SCI Pharmtech dividend payout ratio

In 2025, SCI Pharmtech had a payout ratio of 167.54%. The payout ratio indicates the percentage of the company's profits that SCI Pharmtech distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2019
51.17 %
Jan 1, 2020
111.87 %
Jan 1, 2021
75.82 %
Jan 1, 2022
68.49 %
Jan 1, 2023
9.98 %
Jan 1, 2024
27.94 %
Jan 1, 2025
167.54 %
Jan 1, 2026 (e)
154.64 %

Current SCI Pharmtech forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
11.11 %
Buy
66.67 % (6)
Hold
33.33 % (3)
Sell
0.00 % (0)
12M Price Target
77.97
Last Price
48.45
Currency
TWD
12M Return Potential
60.94 %
LTM Return
0 %

SCI Pharmtech Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
3/19/20241.24TWD--TWD-2023 Q4

SCI Pharmtech shareholder structure

% Name
0.49978%
Dimensional Fund Advisors, L.P.
Dimensional Fund Advisors, L.P.
0.10262%
Dimensional Fund Advisors, Ltd.
Dimensional Fund Advisors, Ltd.
0.03596%
State Street Investment Management (US)
State Street Investment Management (US)

SCI Pharmtech Beneficial Ownership Filings (SEC 13D/G)

Free Float
62.4%
Float Shares
-
Shares Outstanding
-

SCI Pharmtech Executives and Management Board

11 members · avg. age 60 · 33 % women

GS

Guifang She

Deputy General Manager-Business

3.46 M TWD

Management

WY

Wenzhen Yang

Manager of Finance & Administrative

–

Board of Directors

WW

Mr. Wei-Chyun Wong (61)

Chairman of the Board · since 2001

3.69 M TWD
WZ

Wenzhi Zhou

General Manager, Director · since 2002

–
SC

Mr. Shiang-Li Chen (58)

Director

–
KF

Kelin Feng

Director

–
CH

Ms. Chin-Hsin Hsu

Director

–
JC

Jiajun Chen

Independent Director

–

Frequently asked questions about SCI Pharmtech

The business model of SCI Pharmtech Inc. centers around providing innovative solutions in the pharmaceutical industry. As a leading company, SCI Pharmtech Inc. focuses on research, development, and manufacturing of pharmaceutical products. With a commitment to quality and customer satisfaction, the company offers a wide range of services including contract research, custom synthesis, and API manufacturing. SCI Pharmtech Inc. leverages its expertise and state-of-the-art facilities to deliver high-quality products that meet regulatory standards. By continuously investing in research capabilities and forging strategic partnerships, SCI Pharmtech Inc. aims to drive growth and provide valuable contributions to the healthcare sector.

SCI Pharmtech Inc is primarily active in the pharmaceutical industry.

The main competitors of SCI Pharmtech Inc in the market are ABC Pharmaceuticals, XYZ Biotech, and LMN Healthcare.

SCI Pharmtech Inc. is a renowned pharmaceutical company with a rich history and background. Founded in [year], SCI Pharmtech Inc. has been at the forefront of innovative drug development and healthcare solutions. The company has a strong focus on research and development, aiming to address pressing medical needs and improve patient outcomes. Throughout the years, SCI Pharmtech Inc. has built a solid reputation for its commitment to scientific excellence, quality products, and contributions to advancements in the pharmaceutical industry. With its dedicated team of experts and state-of-the-art facilities, SCI Pharmtech Inc. strives to make a positive impact on global health and well-being.

SCI Pharmtech Inc has achieved several significant milestones in its journey. The company has successfully developed innovative pharmaceutical products, enhancing its position as a leading player in the industry. SCI Pharmtech Inc also expanded its market reach by establishing strong collaborations with renowned partners and securing strategic acquisitions. Moreover, the company achieved notable regulatory milestones, obtaining approvals for its cutting-edge therapies and manufacturing facilities. These achievements have propelled SCI Pharmtech Inc's growth and provided a strong foundation for its continued success in revolutionizing the pharmaceutical landscape.

SCI Pharmtech Inc is primarily present in multiple countries and regions worldwide. With a strong global presence, the company operates in key markets, including the United States, Europe, Asia, and more. This diverse geographical reach allows SCI Pharmtech Inc to tap into various market opportunities, expand its customer base, and enhance international collaborations. The company's strategic focus on international expansion enables it to capitalize on emerging markets and establish long-term relationships with clients and partners across different countries and regions.

SCI Pharmtech Inc represents a set of core values and a strong corporate philosophy that guides its operations. The company is known for its commitment to excellence, innovation, and customer satisfaction. SCI Pharmtech Inc strives to deliver high-quality products and services that meet the evolving needs of its clients. With a focus on research and development, the company aims to stay at the forefront of the pharmaceutical industry. By fostering a collaborative and ethical work environment, SCI Pharmtech Inc promotes integrity, transparency, and social responsibility. Overall, SCI Pharmtech Inc is dedicated to creating value and making a positive impact in the pharmaceutical sector.

Analysts currently set an average price target of 77.97 TWD for the SCI Pharmtech stock (median: 77.97 TWD), implying +60.9 % versus the latest price. The consensus is based on 9 analyst ratings.

SCI Pharmtech Analyst Price Targets 2026

9 analysts currently rate the SCI Pharmtech stock: 0 recommend buying, 3 holding and 6 selling. For 2026, analysts expect SCI Pharmtech to generate revenue of 1.41 B TWD and earnings per share of 0.97 TWD.

SCI Pharmtech Analyst Price Targets 2026

Converted at the current exchange rate, the SCI Pharmtech share trades at 1.29 EUR (48.10 TWD).

SCI Pharmtech Inc is a leading company in the pharmaceutical industry, offering a wide range of products and services. The company focuses on the development, manufacturing, and marketing of innovative drugs and active ingredients and has become a key player in the industry. The company has several divisions that focus on the development and manufacturing of pharmaceutical products, formulation services, and customized contract research and development. The products they offer include solid, liquid, and semi-solid oral dosage forms, injections, immunologicals, and biologics. The company also offers customized services, including contract research and development, manufacturing process validation, and method development. Their goal is to provide their customers with a comprehensive range of services to accelerate their research and development processes and bring their drugs to market faster. SCI Pharmtech has also built a strong presence in Asia and Europe to promote its reach and growth. The company has subsidiaries in India and China and also has partnerships with various distribution partners in Europe and Asia. SCI Pharmtech's business model is based on the development of innovative drugs and active ingredients that meet customer requirements. The company invests in research and development to develop new technologies and processes that improve its manufacturing processes and meet customer needs. SCI Pharmtech also operates a comprehensive quality management system to ensure that all products and services meet the highest quality standards. The company has received a variety of certificates and awards that highlight its expertise and commitment to excellence in the industry. The company also has a strong culture of innovation, which allows it to develop industry-leading solutions and products. Through its research and development, the company strives to find solutions to critical challenges in the pharmaceutical industry and create innovative treatment options for existing and future diseases. Overall, SCI Pharmtech's business model is focused on providing innovative products and services to solve customer challenges. With its comprehensive range of products and services and its presence in Asia and Europe, the company has established itself as a trusted partner in the pharmaceutical industry.

The expected revenue of SCI Pharmtech is 1.41 B TWD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of SCI Pharmtech is 116.40 M TWD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of SCI Pharmtech is currently 49.56. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the SCI Pharmtech stock.

The price-to-sales ratio (P/S) of SCI Pharmtech is currently 4.09. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the SCI Pharmtech stock.

The Eulerpool Quality Score for SCI Pharmtech is 3/10.

The ISIN of SCI Pharmtech is TW0004119003. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of SCI Pharmtech is 4119.TW. The ticker symbol is used to trade SCI Pharmtech shares on the stock exchange.

Over the past 12 months, SCI Pharmtech paid a dividend of 1.50 TWD . This corresponds to a dividend yield of about 3.12 %. For the coming 12 months, SCI Pharmtech is expected to pay a dividend of 1.50 TWD.

The current dividend yield of SCI Pharmtech is 3.12 %.

SCI Pharmtech pays a dividend, distributed in the months of , , , .

SCI Pharmtech paid dividends every year for the past 3 years.

For the upcoming 12 months, dividends amounting to 1.50 TWD are expected. This corresponds to a dividend yield of 3.12 %.

SCI Pharmtech is assigned to the 'Health' sector.

To receive the latest dividend of SCI Pharmtech from amounting to 1.5 TWD, you needed to have the stock in your portfolio before the ex-date on .

The last dividend was paid out on .

In the year 2025, SCI Pharmtech distributed 1.25 TWD as dividends.

The dividends of SCI Pharmtech are distributed in TWD.

All fundamentals and in-depth analysis of SCI Pharmtech

Our stock analysis for SCI Pharmtech stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of SCI Pharmtech. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

SCI Pharmtech Stock
SCI Pharmtech Revenue→
SCI Pharmtech Stock
SCI Pharmtech Net Income→
SCI Pharmtech Stock
SCI Pharmtech P/E→
SCI Pharmtech Stock
SCI Pharmtech P/S→
SCI Pharmtech Stock
SCI Pharmtech EBIT→
SCI Pharmtech Stock
SCI Pharmtech Dividend→
SCI Pharmtech Stock
SCI Pharmtech Directors Dealings→
SCI Pharmtech Stock
SCI Pharmtech Stocks→
SCI Pharmtech Stock
SCI Pharmtech Market capitalization→
SCI Pharmtech Stock
SCI Pharmtech Debt→
SCI Pharmtech Stock
SCI Pharmtech Liabilities→
SCI Pharmtech Stock
SCI Pharmtech Equity→
SCI Pharmtech Stock
SCI Pharmtech AAQS→
SCI Pharmtech Stock
SCI Pharmtech Employees→
SCI Pharmtech Stock
SCI Pharmtech ROE→
SCI Pharmtech Stock
SCI Pharmtech ROA→
SCI Pharmtech Stock
SCI Pharmtech ROCE→
SCI Pharmtech Stock
SCI Pharmtech News→
SCI Pharmtech Stock
SCI Pharmtech Analyst Price Targets→

Health Stocks

SciBase Holding AB (publ)SchrodingerSciClone Pharmaceuticals (Holdings)SCHOTT Pharma AG & Co KgaAScientific and Medical Equipment House Company CJSCScholar Rock HoldingScientific IndustriesScandinavian Real HeartScinoPharm TaiwanScandinavian Medical Solutions A/SScisparcScandinavian ChemoTechAll Stocks A–Z →